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The relapsing and progressive nature of bladder tumors, and the heterogeneity in the response to cisplatin-containing
regimens, are the major concerns in the care of urothelial bladder carcinoma (UBC) patients. The metabolic adaptations
that alter the tumor microenvironment and thus contribute to chemoresistance have been poorly explored in UBC setting.
We found signiﬁcant associations between the immunoexpressions of the microenvironment-related molecules CD147,
monocarboxylate transporters (MCTs) 1 and 4, CD44 and CAIX in tumor tissue sections from 114 UBC patients. The
presence of MCT1 and/or MCT4 expressions was signiﬁcantly associated with unfavorable clinicopathological parameters.
The incidence of CD147 positive staining signiﬁcantly increased with advancing stage, grade and type of lesion, and
occurrence of lymphovascular invasion. Similar associations were observed when considering the concurrent expression of
CD147 andMCT1. This expression proﬁle lowered signiﬁcantly the 5-year disease-free and overall survival rates. Moreover,
when selecting patients who received platinum-based chemotherapy, the prognosis was signiﬁcantly worse for those with
MCT1 and CD147 positive tumors. CD147 speciﬁc silencing by small interfering RNAs (siRNAs) in UBC cells was
accompanied by a decrease in MCT1 and MCT4 expressions and, importantly, an increase in chemosensitivity to cisplatin.
Our results provide novel insights for the involvement of CD147 andMCTs in bladder cancer progression and resistance to
cisplatin-based chemotherapy.We consider that the possible cooperative role of CD147 andMCT1 in determining cisplatin
resistance should be further explored as a potential theranostics biomarker. © 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Urothelial bladder carcinoma (UBC), the most
frequent type (90%) of bladder cancer and the second
most common urogenital malignancy, is a complex
disease with variable natural history and clinical
behavior. The majority of the tumors are non-muscle
invasive (NMI) low-grade papillary lesions character-
ized by frequent recurrences; the remaining display
a phenotype of muscle-invasive (MI) tumors. An
intermediate sub-variant of high-grade NMI tumors
harbors an enhanced risk of progression [1]. Due to
the high propensity of dissemination, MI tumors are
generally treated by radical cystectomy (RC), pelvic
lymphadenectomy and/or perioperative cisplatin-
containing chemotherapy [2]. However, chemother-
apy responses are very heterogeneous and frequently
impaired by resistance [3].
CD147 (or EMMPRIN, extracellular matrix metal-
loproteinase inducer) is a transmembrane protein
member of the immunoglobulin superfamily of
receptors. Originally identified as a matrix metal-
loproteinase (MMP) inducer, CD147 also promotes
angiogenesis,migration and invasion [4]. Importantly,
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CD147, throughhyaluronan-CD44 interaction, cross-
talks with various multi-drug transporters of the ABC
(ATP-binding cassette) family classically associated
with anti-apoptotic signaling and chemotherapy
resistance [5]. Moreover, these constitutive interac-
tions contribute to the regulation of monocarbox-
ylate transporter localization and function at the
plasma membrane [6].
Monocarboxylate transporters (MCTs) comprise
fourteenmembers that share the same basic structure,
although only the membrane-bound proton-coupled
isoforms—MCT1,MCT2,MCT3, andMCT4–transport
monocarboxylates, namely lactate, through the
plasma membrane [7]. The efflux of lactate from the
malignant cells to the tumor microenvironment is
crucial tomaintainmetabolic homeostasis. Themalig-
nant cells usually display high glycolytic rates even
under aerobic conditions, a phenomenon known as
the “Warburg effect” [8]. Hypoxia, a constitutive trait
of tumors, is considered to be a trigger mechanism of
the glycolytic phenotype [9]. Under hypoxic stress,
hypoxia-inducible factor (HIF)-1a amplifies an adap-
tive response that promotes glycolysis and induces the
expression of pH regulators, such as carbonic anhy-
drase IX (CAIX) and MCTs, to assure intracellular
pH balance. The high amounts of lactate extruded
from the malignant cells, mainly through MCT1 and
MCT4, contribute to acidification of the tumor
microenvironment, supporting increased migration
and invasion abilities of the primary tumor [10].
The preponderance of the tumormicroenvironment
in UBC setting has been poorly explored. A few studies
have reported upregulation of microenvironment-
related molecules, namely CD147 [11–13], CD44
[14], CAIX [15], and MCT4 [16], and their significant
impact on the prognosis of the patients. Als et al. [12]
demonstrated thatCD147positivitywas able topredict
response and survival following cisplatin-containing
chemotherapy in patients with advanced UBC. In
other types of malignancies, increasing evidence
suggest that the upregulation of the aforementioned
molecules contributes to a hyper-glycolytic acid-
resistantmicroenvironment that favors tumor growth,
invasion and metastasis, suppresses host immune
defences, and impairs chemotherapy response [17–19].
In order to elucidate the role of microenvironment-
related molecules in UBC, namely their impact on
chemoresistance, we aimed to assess, in 114 UBC
patients, the clinical and prognostic significance of
MCT1, MCT4, CD147, CD44, and CAIX expressions.
Additionally, we intended to characterize the chemo-
sensitivity of parental and CD147-silenced UBC cell
lines to cisplatin.
MATERIALS AND METHODS
Patients and Tissue Samples
Representative formalin-fixed paraffin-embedded
surgical specimens were obtained from 114 patients
with urothelial bladder carcinomas who underwent
transurethral resection (TUR) and/or radical cystec-
tomy (RC) at the Portuguese Institute of Oncology,
Porto, from January 1996 to May 2006. In our cohort,
we did not include patients diagnosed with urothelial
carcinomas with variant histology, squamous cell or
adenocarcinomas, patients who had an insufficient
follow-up time and/or patients whose tumor samples
were inadequate for further study. Prior approval was
obtained from the Ethics Committee of the Portu-
guese Institute of Oncology. The median age of the
patients was 70 yr (range 41–86); ninety-four (82.5%)
were male and twenty (17.5%) were female. Addi-
tionally, tissue sections were obtained from normal-
like areas of the urinary bladder of six autopsy patients
without history of bladder cancer.
Each surgical product was examined according to
the guidelines of the College of American Patholo-
gists [20]. Hematoxylin–eosin (H&E)-stained sections
were reviewed according to standard histopatholog-
ical examination by two independent pathologists.
Lesions were classified according to the American
Joint Committee on Cancer (AJCC) [21] and to the
World Health Organization (WHO) [22] classification
systems. For statistical analysis, tumors were divided
into three groups based on T stage.
Forty-two (36.8%) patients underwent TUR
with curative intention; 22 of these patients were
treated by RC following disease recurrence and
progression or when multiple carcinoma in situ
(CIS) lesions were observed in the pathological
specimen. Seventy-two (63.2%) patients had RC as
their first treatment. Platinum-based chemotherapy
regimens were administered to 31 (27.2%) patients
(neoadjuvant: six patients, adjuvant: nine patients,
palliative: 16 patients). Twenty-seven (23.7%)
patients presented loco-regional metastases at the
time of RC. Mean and median follow-up were 38.2
and 37.0 months (range 1–132), respectively. Recur-
rence was defined as the reappearance of UBC (loco-
regional dissemination or distant metastasis) more
than three months after TUR/RC, occurring in 74
(64.9%) patients. Disease-free survival (DFS) was
defined as the time from the TUR/RCuntil recurrence.
Overall survival (OS) was defined as the time from the
TUR/RC until death by bladder cancer or the last
clinical assessment.
Cell Lines and General Cell Culture Procedures
In the present study, four urothelial bladder
carcinoma cell lines were used. As we intended to
characterize the chemosensitivity of the cell lines
to cisplatin (the platinum compound usually admin-
istered to patients with muscle-invasive tumors), we
selected aNMI-UBC cell line (5637) and threeMI-UBC
cell lines (T24, MCR, and HT1376). T24 was obtained
from Leibniz Institute DSMZ—German Collection of
Microorganisms and Cell Cultures; 5637, MCR and
HT1376 were kindly provided by Professor Paula
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Videira, Universidade Nova de Lisboa, Lisboa,
Portugal. Cell line authentication was performed by
Pinto-Leite et al. [23]; genotyping confirmed their
complete identity. The cell lines were cultured as a
monolayer in RPMI Medium 1640 (Gibco1) supple-
mented with antibiotics (1% penicillin/streptomycin
solution, Gibco1) and 10% fetal bovine serum (FBS,
Gibco1). Cells were incubated in a humidified
atmosphere at 378C and 5% CO2, and were routinely
subcultured by trypsinization.
Immunohistochemistry and Immunocytochemistry
Representative 4-mm-thick UBC sections were
stained by immunohistochemistry, according to
the streptavidin-biotin-peroxidase complex technique
(Ultravision Detection System Anti-polyvalent, HRP,
Lab Vision Corporation, Waltham, MA) for MCT4,
CD147, CD44, andCAIXdetection, and to the avidin–
biotin–peroxidase complex assay (VECTASTAIN Elite
ABC Reagent, RTU, Vector Laboratories, Burlingame,
CA) for MCT1 detection, as previously described
[13,24,25]. The primary antibodies were obtained
from Chemicon1 (MCT1, AB3538P), Santa Cruz
Biotechnology1 (MCT4, H-90, sc-50329), Zymed1
(CD147, 18–7344), AbD Serotec (CD44, MCA2726)
and AbCam (CAIX, ab15086). These antibodies were
used in 1:200 dilution (MCT1), 1:500 dilution (MCT4
and CD147), 1:1000 dilution (CD44) and 1:2000
dilution (CAIX), and incubated on the sections for 2h
(MCT4, CD147, CD44, CAIX) or overnight (MCT1), at
room temperature. Negative controls were carried out
by replacing the primary antibodies with a universal
negative control antibody (N1699, Dako, Glostrup,
Denmark). Colon carcinoma and gastric carcinoma
sections were used as positive controls for MCT1,
MCT4, CD147 and CD44 detection, and for CAIX
detection, respectively.
The immunocytochemistry procedure for detecting
MCT1, MCT4, and CD147 expression in the UBC cell
lines was performed in 4mm-thick cytoblock sections,
following the protocol mentioned for UBC sections,
as described above. The paraffin cytoblocks were
made from concentrated cell suspensions by
centrifuging fresh cell suspensions at 1200 rpm for
5min. Cell pellets were incubated overnight with
formaldehyde 3.7%, re-centrifuged, processed in an
automatic tissue processor (TP1020, Leica, Nussloch,
Germany), and then included into paraffin (block-
forming unit EG1140H, Leica).
Evaluation of Immunohistochemistry and
Immunocytochemistry Results
The immunostained tissue sections were evaluated
by light microscopy for cytoplasmic and/or plasma
membrane staining by two independent observers.
Discordant cases were re-evaluated and classified by
consensus. The grading system used was semi-
quantitative [13,24–25], considering the sum of the
percentage of immunoreactive cells (0, 0% of positive
cells; 1, <5% of positive cells; 2, 5–50% positive cells;
score 3, >50% of positive cells) and the intensity
of staining (0, negative; 1, weak; 2, intermediate; 3,
strong); final scores 4 were considered positive for
all of the biomarkers studied. Finally, the plasma
membrane positive cases were analyzed separately.
The expression of the biomarkers on the cytoblocks
sections was also assessed, distinguishing between
cytoplasmic and plasma membrane staining.
Downregulation of CD147 Expression
Silencing of CD147 expression inMCR andHT1376
cell lines was accomplished by reverse transfection
of 50nM siRNA (siRNA for CD147, SASI_Hs01_
00156882, Sigma–Aldrich1; St. Louis, MO, control
scramble siRNA, 4390843, Ambion1); lipofectamine
(13778-075, InvitrogenTM) was used as permeabi-
lization agent, following the manufacturer’s instruc-
tions. Cells were transfected once and collected on
days 5 and 8 after transfection. Specific silencing of
the targeted gene was confirmed by Western blotting
and reverse transcription polymerase chain reaction
(RT–PCR) analysis.
Western Blotting
Parental UBC cell lines grown to 80% confluence,
and siRNA cells grown until days 5 and 8 after
transfection, were scraped in cold PBS and then
homogenized in lysis buffer (supplemented with
protease inhibitors) for 10min. Cell lysates were
collected after centrifugation at 13,000 rpm, 15min
at 48C. The Bio-Rad Dc Protein Assay (500-0113, Bio-
Rad, Hercules, CA) was used for protein quantifica-
tion. Equal amounts (20mg) of total protein were
separated on 10% polyacrylamide gel by SDS–PAGE
and transblotted onto nitrocellulose membranes
(Amersham Biosciences) in 25mM Tris-base/glycine
buffer. MCT1, MCT4 and CD147 expressions were
evaluated by incubating the membranes overnight at
48C with specific primary polyclonal antibodies
against MCT1 (1:200 dilution, H-1, sc-365501, Santa
Cruz Biotechnology1), MCT4 (1:2000 dilution, H-90,
sc-50329, Santa Cruz Biotechnology1) and CD147
(1:200 dilution, sc-71038, Santa Cruz Biotechnolo-
gy1).b-Actin (1:300 dilution, I19, sc-1616, SantaCruz
Biotechnology1) was used as loading control. Blots
were developed with enhanced chemiluminescence
(SupersignalWest Femto kit, 34096, Pierce,Waltham,
MA) using anti-mouse or anti-goat Ig secondary
antibodies coupled to horseradish peroxidase. Band
densitometry analysis with the Image J software
(version 1.41, National Institutes of Health) was
performed for quantification of Western blot results.
RT-PCR Assay
Total cellular RNA was extracted using TRIzol
reagent (15596-026, Ambion1, Austin, TX) and their
concentration determined spectrophotometrically in
a Nanodrop 2000 (Thermo Scientific Inc., Waltham,
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MA). 1mg RNA was reverse-transcribed using a high
capacity cDNA reverse transcription Kit (4368814,
Applied Biosystems1, Carlsbad, CA), according to
the manufacturer’s instructions. The primer sequen-
ces used were for CD147 RT-PCR were (sense) 50-
CCATGCTGGTCTGCAAGTCAG-30 and (antisense)
50-CCGTTCATGAGGGCCTTGTC-30, and to b-actin
RT-PCR were (sense) 5’-CTGGAACGGTGAAGGT-
GACA-30 and (antisense) 50-AAGGGACTTCCTGTAA-
CAACGCA-30. Primer annealing occurred at 558C for
30 s during 30 cycles for CD147, and at 568C for 30 s
during 35 cycles for b-actin. The PCR products were
analyzed on a 2% agarose gel containing ethidium
bromide.
Cell Viability Assay
To assess the chemosensitivity of the UBC cell lines
to cisplatin (CDDP, cis-diamminedichloroplatinum-
[II])s, cells were seeded in triplicate into 48-well plates
at different densities, based on the growth character-
istics of each cell line (1.2104 T24 and 5637 cells per
well, 1.5104HT1376 cells per well, 2104MCR and
siRNA-HT1376 cells per well and 3104 siRNA–MCR
cells per well), and incubated for 2 (non-siRNA cell
lines) or 5 (siRNA cell lines) days. The medium was
then removed and replaced with fresh medium
containing CDDP with varying concentrations (1–
100mg/ml). Stock solutions of 1mg/ml CDDP in 10%
NaCl were kindly provided by the Pharmaceutical
Services of the Portuguese Institute of Oncology,
Porto, Portugal, from which the working solutions
were prepared. The effect of the treatment with CDDP
on cell viability was determined at 72h by the MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetra-zolium) assay
(G3580, Promega, Madison, WI) according to the
manufacturer’s instructions. The IC50 values (CDDP
concentration that corresponds to 50% of cell growth
inhibition) were estimated from at least three indepen-
dent experiments, using GraphPad Prism 5 Software.
Cell Cycle Analysis
Cells were seeded in 6-well plates at different
densities (5105 T24 and 5637, 8105 HT1376
and 1106 MCR cells per well). After 42h of
incubation, the cells were starved in FBS-free medium
during 6h, and then treated with the specific CDDP
IC50 dose during 72h. Cells were trypsinized andfixed
in 70% ethanol (30min at 48C), followed by staining
with propidium iodide (PI) solution (20mg/ml of PI
[81845, Sigma]þ250mg/ml of RNAse [12091-021,
InvitrogenTM] diluted in 0.01% Triton X-100 in PBS)
at 508C during 50min. PI stained cells were analyzed
by flow cytometry (LSRII model, BD Biosciences,
San Jose, CA), considering a total of 15.000 events,
and the cell cycle distribution was determined with
the FlowJo software (version 7.6, Tree Star, Inc,
Ashland, OR). The assay was repeated at least three
times.
Cell Death Assay
Cell death rate was determined by the Annexin-V-
FLOUS staining Kit (Roche Diagnostics). Cells were
seeded in 6-well plates at different densities (5105
T24 and 5637, 8105 HT1376 and 1106 MCR cells
per well). After 48h of incubation, cells were treated
with the specific CDDP IC50 dose during 72h,
followed by collection and staining with annexin
V/PI, according to the manufacturer’s instructions
(15min of incubation in the staining solutions, at
room temperature). The percentage of cell death was
assessed by flow cytometry (LSRII model, BD Bioscien-
ces), considering a total of 20,000 events, and the results
were analyzed using the FlowJo software (version 7.6,
Tree Star, Inc). The assay was repeated at least three
times.
Statistical Analysis
The immunohistochemistry results were analyzed
using the Statistical Package for Social Sciences (SPSS)
software for Windows, version 18.0. Associations
between the immunoexpression of the biomarkers
and the clinicopathological parameters were exam-
ined for statistical significance using Pearson’s chi-
square (x2) test and Fisher’s exact test (when n<5).
Five-year DFS and OS rates were evaluated using
Kaplan–Meier curves and differences were analyzed
by Log-Rank or Breslow tests. P values lower than 0.05
were considered significant. Variables that achieved
statistical significance in the univariate analysis were
entered in a multivariate analysis using Cox propor-
tional hazards analysis.
The results of the in vitro studies were analyzed
using the GraphPad Prism 5 software, with the
Student’s t-test, considering significant P values lower
than 0.05.
RESULTS
Characterization of MCT1, MCT4, CD147, CD44 and
CAIX Expressions in Urothelial Bladder Tumors
Prognostic significance of the clinicopathological
parameters
The 5-year DFS and OS rates were significantly
influenced by T3/T4 pathologic stage (P<0.001),
muscle-invasive type of lesion (P<0.001), occurrence
of lymphovascular invasion (DFS, P¼0.002; OS,
P<0.001) and presence of loco-regional metastases
(DFS, P¼0.007, OS, P<0.001) (data not shown).
Immunoexpression of the biological parameters
A total of 114 UBC samples and six non-neoplastic
bladder samples were analyzed for MCT1, MCT4,
CD147, CD44, and CAIX expressions. After testing
different grading systems considering the semi-
quantitative evaluation of extension and intensity
of staining (cytoplasmic expression, with or without
plasma membrane staining), we adopted the final
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immunoreaction score 4 as the more suitable for
explaining the results obtained with all of the studied
biomarkers, as described by others [26]. Due
to the membrane localization of the biomarkers,
plasma membrane staining was additionally assessed
separately.
Regarding MCT1 and MCT4 immunoexpressions
(Figure 1A-i and ii, respectively), 36 (31.6%) and 50
(43.9%) UBC cases were scored positive, respectively;
plasma membrane staining was observed in 44
(38.6%) and 64 (56.1%) cases, respectively. Stromal
and endothelial cells were negative for both biomark-
ers, and served as internal negative controls. None of
the normal bladder samples expressed MCT1; two
non-neoplastic sections showed cytoplasmic staining
for MCT4, but the plasma membrane was negative in
the six observed sections.
When considering the expressionof the chaperones
CD147 andCD44 (Figure 1A iii, iv and v, respectively),
themajority of the tumor tissues was positive both for
global immunoreaction [CD147: 68 (59.6%); CD44:
57 (50.0%)] and plasma membrane staining (CD147:
70 [61.4%]; CD44: 77 [67.5%]). The stroma was
negative for CD147 immunoreaction in all of the
cases (Figure 1A-iii); however, althoughCD44positive
tumors presented negative stromas (Figure 1A-iv),
CD44 negative tumors had their stromal cells stained
(Figure 1A-v). Regarding the non-neoplastic bladder
samples, the majority was negative for CD147
staining, while no difference was observed when
evaluating CD44 expression.
CAIX positive immunoexpression (Figure 1A-vi)
was observed in the vast majority of the UBC samples
(global immunoreaction: 72 [63.2%]; plasma mem-
brane staining: 92 [80.7%]); plasma membrane posi-
tive cases exhibited a heterogeneous pattern, with the
luminal face ofNMI papillary lesions and the centre of
MI lesions presenting a strong intensity of staining.
None of the normal bladders expressed CAIX.
Associations among the biological parameters
Significant associations were found between the
expression of MTCs, CD147, and CD44 in the tumor
samples (Table 1). CD147 and CD44 immunoreaction
was also correlated: 70.2% (40/57) and 67.5% (52/77)
of the positive sections for CD44 (global expression
andplasmamembrane staining, respectively) expressed
CD147 (P¼0.035 and P¼0.065, respectively; data
not shown). Additionally, significant associations
were found when comparing immunoreactive sam-
ples for MCT4 (92%, 46/50, P¼0.007), CD147
(86.9%, 59/68, P¼0.046) and CD44 (89.5%, 51/57,
P¼0.018) with CAIX plasma membrane positive
cases (data not shown).
Clinical and prognostic significance of the biological
parameters
The presence of MCT1 and/or MCT4 global
immunoexpression, and MCT1 plasma membrane
staining, was significantly associated with unfavour-
able clinico-pathological parameters, such as increas-
ing stage, MI type of lesion and occurrence of
lymphovascular invasion (Table 2). MCT1 expression
(global immunoreaction) had a negative influence
on 5-year DFS (P¼0.053) and OS (P¼0.065) rates
(Figure 1B).
Regarding CD147 expression, 80.0% of pT3/pT4
tumors, 75.0% of MI tumors and 84.6% of the tumors
with LVI occurrence were positive for CD147 global
immunoexpression (Table 2). This expression profile
lowered significantly the 5-year DFS (P¼0.027) and
OS (P¼0.018) rates (Figure 1B).
In order to assess the clinical and prognostic
significance of the combined analysis of MCT1 and
CD147 immunoreaction, we considered two groups:
group 1, including cases with 0 or 1 positive
biomarkers, and group 2, including cases with two
positive biomarkers. Group 2had unfavorable clinico-
pathological parameters—72.7% (24/33, P<0.001),
90.9% (30/33, P<0.001), and 60.6% (20/33,
P<0.001) of the MCT1 and CD147 positive cases
were pT3/pT4, MI and with LVI occurrence tumors,
respectively (data not shown)—and a lower 5-year
DFS (P¼0.033) and OS (P¼0.037) (data not shown).
Notably, when selecting the patients who received
platinum-based chemotherapy (n¼31), the prognosis
was significantly worse for group 2 (n¼11)—patients
with 0 or 1 positive biomarkers had median DFS and
OS times of 25.8 (95%CI 20.4–31.2) and 42.2 (95%CI
33.9–50.4) months, respectively, which were reduced
to 11.7 (95% CI 6.7–16.2) and 12.4 (95% CI 1.0–32.5)
months, respectively, if the tumors were MCT1 and
CD147 positive (P¼0.072 and 0.026, respectively;
Figure 1B).
CD44 plasma membrane positivity was predomi-
nant in pT3/pT4 and MI UBC samples. Conversely,
the majority of high-grade papillary lesions were
CAIX positive. Regarding the global immunoreaction
for CAIX, 87.5% of high-grade papillary tumors,
69.3% of the tumors without LVI occurrence and
67.8% of the cases without loco-regional metastasis
were scored positive (Table 2).
The aforementioned associations were found
when analyzing a series of 114 UBC patients,
which includes six patients that received neo-
adjuvant platinum-based chemotherapy regimens.
Since this could introduce a bias variable, the
statistical analysis was also performed without those
six cases; however, no differences were observed,
and we decided to include the cases in the final
results.
Multivariate Analysis
The parameters that significantly influenced the
5-year DFS and OS rates were entered in the
multivariate analysis model. None of the aforemen-
tioned variables was identified as an independent
prognostic factor.
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Immunoexpression of MCT1, MCT4 and CD147 in
Urothelial Bladder Cancer Cell Lines
All UBC cell lines expressed MCT1, MCT4, and
CD147, as detected by Western blot (Figure 2A) and
immunocytochemistry (Figure 2B).MCT4 andCD147
were expressed predominantly at the plasma mem-
brane. In T24 cell line, MCT1 expression was
membranous, while in the remaining cell lines,
both plasma membrane and cytoplasm were stained.
Figure 1. Immunohistochemical positive reactions (A) for MCT1 (i,
200 ampliﬁcation), MCT4 (ii, 100 ampliﬁcation), CD147 (iii, 200
ampliﬁcation), CD44 (iv,100 ampliﬁcation; v,40 ampliﬁcation) and
CAIX (vi,100 ampliﬁcation) in urothelial bladder carcinoma cells, and
inﬂuence of selected biomarkers on survival rates (B). A, ii to iv, muscle-
invasive tumors exhibiting cytoplasmic and membrane immunoex-
pression of the selected biomarkers in the malignant urothelium, with
negative stromas; v, a non-muscle invasive tumor showing an inverted
CD44 staining pattern, with negative malignant cells and positive
stroma; vi, a muscle-invasive tumor stained for CAIX in the plasma
membrane of the malignant urothelial cells, where the tumor core
is signiﬁcantly more intensely stained than the invasive front. B,
Kaplan–Meier curves demonstrating 5-year disease-free survival and
overall survival rates based on MCT1 or CD147 immunoexpression
status in bladder tumor sections (n¼ 114), and on MCT1 and
CD147 concomitant immunoexpression in selected platinum-treated
patients (n¼ 31). Log-Rank or Breslow tests were used to determine
P values.
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In Vitro Effect of CDDP in Urothelial Bladder Cancer
Cell Lines
In order to characterize the response of four
different parental UBC cell lines to CDDP, IC50 values
were estimated after 72h of treatment (Figure 3A)
(previous protocol optimization, with incubation
periods of 24, 48 and 72h, was done). We observed
that 5637 and T24 cell lines present a gradual decrease
in total biomass in a CDDP dose-dependent manner.
HT1376 and MCR cell lines were less sensitive to
CDDP effect: at the initial concentrations, only a
slight decrease on cell viability was noted. To further
elucidate CDDP effect on cell cycle distribution
(Figure 3B) and cell death (Figure 3C), the UBC cell
lines were treated with the CDDP IC50 predetermined
doses. 5637, T24, and HT1376 cell lines presented a
decrease in G1 phase and an increase in Sþ subG1
phase’s cell populations (differences statistically
significant for T24 and HT1376). The drug induced
cell death in 5637 and T24 cell lines: we observed a
marked increase in late apoptotic/necrotic cell pop-
ulations (differences statistically significant for 5637).
Regarding the cell cycle distribution of MCR cell line,
we observed a significant decrease in G1 and an arrest
in SþG2 phase’s cell populations. We confirmed this
cytostatic action of the drug inMCR cells through the
cell death assay.
Effect of CD147 Downregulation on Urothelial Bladder
Cancer Cells' Biology and Response to CDDP Treatment
The characterization of the effect of CDDP treat-
ment on cell viability, cell cycle distribution and cell
death, allowed us to choose two of the cell lines for
subsequent downregulation studies. HT1376 and
MCR cells seem to be less sensitive to CDDP effect.
Based on this, we used specific siRNA targeting CD147
mRNA to downregulate CD147. By Western blotting,
we confirmed amarked decrease in CD147 expression
in both cell lines, most notably following 6 and
10 days after reverse transfection; the transfection
with scramble siRNA did not alter protein expression.
Once the protocol has been optimized, we proceeded
with CDDP treatment in siRNA-HT1376 and siRNA-
MCR cells. Sincewe had previously determinedCDDP
IC50 values for the parental cell lines after 72h of
exposure to the drug, we followed the same procedure
with the siRNA cell lines, by treating the cells between
days 5 and 8 after reverse transfection. However,
we were only able to continue the experiment with
HT1376 cell line, since MCR cells became non-viable
after transfection plus CDDP treatment (confirmed
in repeated assays). CD147 silencing at days 5 and 8
after transfection was confirmed by Western blot and
RT-PCR (Figure 4A and B); the decrease in CD147
expression was accompanied by a decrease in MCT1
and MCT4 expressions (Figure 4A). IC50 values were
determined (Figure 4C), which allowedus to conclude
that siCD147-HT1376 cells were more sensitive to
CDDP treatment than siScramble-HT1376 cells (the
disparity between IC50 values for parental HT1376
and siScramble-HT1376 cells is due to the different
number of cells plated per well).
DISCUSSION
Radical cystectomy with bilateral lymphadenecto-
my provides a cure for most of the UBC patients
with muscle-invasive organ-confined lesions [2], but
regional lymph node and visceral metastases are
frequently found; in these cases, perioperative che-
motherapy in fit patients is mandatory. Multi-drug
platinum-based regimens provide the best response
rates. Cisplatin is the main component of the MVAC
Table 1. Association Between MCTs, and CD147 and CD44 Global Immunoreaction (Cytoplasmic Expression, With or
Without Plasma Membrane Staining) or Plasma Membrane Immunoexpression
n
CD147 CD44
Negative (%) Positive (%) Pa Negative (%) Positive (%) Pa
MCT1
Global immunoreaction
Negative (%) 78 43 (55.1) 35 (44.9) <0.001 46 (59.0) 32 (41.0) 0.008
Positive (%) 36 3 (8.3) 33 (91.7) 11 (30.6) 25 (69.4)
Plasma membrane
Negative (%) 70 34 (48.6) 36 (51.4) 0.006 26 (37.1) 44 (62.9) 0.220
Positive (%) 44 10 (22.7) 34 (77.3) 11 (25.0) 33 (75.0)
MCT4
Global immunoreaction
Negative (%) 64 41 (64.1) 23 (35.9) <0.001 40 (62.5) 24 (37.5) 0.004
Positive (%) 50 5 (10.0) 45 (90.0) 17 (34.0) 33 (66.0)
Plasma membrane
Negative (%) 50 26 (52.0) 24 (48.0) 0.012 21 (42.0) 29 (58.0) 0.070
Positive (%) 64 18 (28.1) 46 (71.9) 16 (25.0) 48 (75.0)
ax2 or Fisher’s exact tests.
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Figure 2. CD147 and monocarboxylate transporters (MCT1 and MCT4) expressions in bladder cancer cell lines,
as detected by Western blot (A; molecular weights: 50–60 kDa for the highly glycosylated and 42 kDa for low
glycosylated form of CD147, 50 kDa for MCT1, and 52 kDa for MCT4) and immunocytochemistry (B, 400
ampliﬁcation). The biomarkers were expressed by the four UBC cell lines. The pattern of expression was
predominantly membranous. 5637, HT1376 and MCR additionally exhibited a strong cytoplasmic immunoreaction
for MCT1.
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(methotrexate, vinblastine, adriamycin, and cisplat-
in) and GC (gemcitabine and cisplatin) combinations
generally used to treat MI-UBC patients [27]. This
“alkylating-like” agent exerts clinical activity against
several solidmalignancies, namely testicular, bladder,
ovarian, colorectal, lung and head, and neck can-
cers [28]. However, many patients are intrinsically
resistant to cisplatin-based regimens, while others are
initial responders but will eventually develop
resistance [3].
Although poorly explored in UBC setting, the
influence of the metabolic transformation events
that alter the tumor microenvironment and thus
mediate malignant progression and dissemination
is gaining particular attention. In fact, solid malig-
nancies are characterized by hypoxic regions and
Figure 3. Effect of CDDP on the viability of bladder cancer cell lines
(A), as detected by the MTS assay after 72 h of treatment. Results are
expressed as the mean standard deviation of at least 3 independent
experiments, each one in triplicate. The equation for IC50 determination
is Y¼ Bottomþ (ToP Bottom)/(1þ 10^((LogIC50-X)HillSlope)). T24
and 5637 viability was inhibited in a dose-dependent manner; HT1376
and MCR were less sensitive to CDDP effect at the initial
concentrations. Cell cycle (B) and cell death (C) analysis of bladder
cancer cell lines after 72 h of treatment with IC50 values of CDDP, as
detected by the propidium iodide (PI) and the Annexin V/PI assays,
respectively (ﬂow cytometry). Results are expressed as the mean
standard deviation of at least 3 independent experiments. P< 0.05,
compared IC50 CDDP with NaCl. Representative dotplots of cell
population distribution stained for Annexin V and PI are shown (cell
population in bottom/left (black dots)¼ viable cells; cell population
in upper/right¼ death cells (red dots, late apoptosis; green dots,
necrosis)]. CDDP exerted a cytotoxic effect on T24 and 5637 cell lines,
as conﬁrmed by an increase in subG1 phase cell populations, in the
cell cycle analysis, and an increase in late apoptotic/necrotic cell
populations, in the cell death analysis. HT1376 and MCR cells were
arrested in S phase (cell cycle analysis), and no difference was observed
between control and treated conditions in the cell death analysis, which
denotes a cytostatic action of CDDP.
CD147 AND MCT1 IN BLADDER CANCER 11
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increased anaerobic and aerobic glycolysis, acidic-
promoting conditions that facilitate metastasis and
chemoresistance [29]. In order to further unravel the
role of microenvironment-related molecules in blad-
der cancer, we initiated our study by characterizing
the clinico-pathological and prognostic significance
of MCT1, MCT4, CD147, CD44, and CAIX in a cohort
of 114 UBC patients.
To our knowledge, this is the first study evaluating
MCTs expression in bladder tumor tissue. We found a
considerable percentage of tumor sections positive for
MCT1 andMCT4. Themalignant cells were stained in
the cytoplasm and/or in the plasma membrane. The
biomarkers were largely absent in the non-neoplastic
sections. Plasma membrane expression was only
relevant for MCT1, which probably indicates that
this isoform is essential for the transport of lactate
from the malignant glycolytic cells to the extracellu-
lar milieu. Additionally, the cytoplasmic expression
found for both biomarkers possible denotes their
accessory role in the metabolism of UBC cells, by
transporting monocarboxylates, namely lactate and
pyruvate, across themembranes of cellular organelles.
In fact, MCT1 and MCT4 have also been localized in
themitochondrialmembrane [30]. UBC patients with
positive tumors, particularly for MCT1, displayed
unfavorable clinico-pathological profiles. In accor-
dance, MCTs upregulation has also been observed in
other malignant contexts [17,24,31].
In vivo and in vitro studies have described CD147
has a chaperone for MCT1 and MCT4 [32,33], which
was similarly supported by immunoexpression stud-
ies with human tissues [17,31]. In our UBC cohort,
MCT1 and MCT4 expressions were also significantly
correlated with CD147 expression. Besides its func-
tion as a chaperone, CD147 directly promotes the
malignant phenotype, being upregulated in several
tumor types [17,31]. We have previously demonstrat-
ed that CD147 overexpression, included in amodel of
UBC aggressiveness, facilitates the discrimination of
bladder cancer patients’ prognosis [13]. In the current
study, CD147 was upregulated in bladder tumor
tissue, significantly associating with tumor aggres-
siveness and poor prognosis. In accordance, a few
studies have identified CD147 expression in UBC as
an independent prognostic factor [11,12], being able
to predict response to cisplatin-containing regi-
mens [12]. In our cohort, the concurrent expression
Figure 3. (Continued )
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of MCT1 and CD147 significantly associated with
unfavorable clinico-pathological parameters and
poor prognosis. Other studies with distinctmalignan-
cies have demonstrated that the prognostic value of
CD147 is associated with its co-expression with
MCT1 [34]. MCTs seem to be necessary for proper
membrane expression of CD147 [35], and a coopera-
tive role between the two types of biomarkers in
determining chemotherapy resistance has been pro-
posed [16]. Although the number of eligible cases was
low, the CD147/MCT1 double-positive profile dis-
criminated, in our UBC cohort, a poor-prognosis
group within patients who received platinum-based
chemotherapy. Thus, besides acting as lactate trans-
porters and pH regulators, MCTs may also play
indirect roles in angiogenesis, invasion, malignant
dissemination and chemoresistance, by regulating
and interacting with CD147. It has been described
that CD147 enhances tumor growth and chemo-
resistance via the phosphatidylinositol 3-kinase
(PI3K)/Akt pathway in a hyaluronan-dependent
manner [36]. In fact, CD147 stimulates hyaluronan
production [37]. Besides its important structural
function, this ubiquitous glycosaminoglycan plays
also instructive roles in signaling via binding to
specific cell-surface receptors, namely CD44 [38].
CD44 is a multifunctional transmembrane glycopro-
tein involved in cell adhesion and migration [39]. In
our study, we observed that the majority of the UBC
samples expressed CD44, mainly at the plasma
membrane, which was significantly correlated with
tumor progression. These results are in agreement
with those obtained by other authors [14,40]. More-
over, there was a substantial concordance between
plasma membrane expression of MCTs and CD44, on
one hand, and CD147 and CD44, on the other hand.
It has been demonstrated that constitutive interac-
tions among hyaluronan, CD44, and CD147 contrib-
ute to regulate MCTs localization and function [6].
Our results seem to support that theory. We may
hypothesise that this interactive profile points out for
a probable partnership between CD44, MCTs. and
CD147 in regulating the hyper-glycolytic and acid-
resistant phenotype, and also chemotherapy resis-
tance. CD147 stimulates hyaluronan production [37],
but lactate also induces synthesis of hyaluronan
and expression of CD44 variants in stromal and
Figure 4. Effect of CD147 downregulation in HT1376 cell line on the
expression of MCTs and on chemosensitivity to CDDP (treatment with
CDDP between days 5 and 8 after reverse transfection). A,Western blot
analysis of CD147, MCT1 and MCT4 expressions in control/scramble
HT1376 cells and in siCD147 HT1376 cells showing that CD147
silencing was accompanied by a decrease in MCT1 and MCT4
expressions (molecular weights: 50–60 kDa for the highly glycosylated
and 42 kDa for low glycosylated form of CD147, 50 kDa for MCT1, and
52 kDa for MCT4). B, RT-PCR analysis of CD147 expression in control/
scramble HT1376 cells and in siCD147 HT1376 cells conﬁrming its
suppression at the RNA level at days 5 and 8 after reverse transfection
(molecular weight of CD147: 196 bp). C, effect of CDDP on the viability
of scramble and siCD147-HT1376 cells, as detected by the MTS assay
after 72 h of treatment, showing that siCD147 cells weremore sensitive
to CDDP. Results are expressed as the mean standard deviation of at
least 3 independent experiments, each one in triplicate. P< 0.05,
compared IC50 from scramble cells with siCD147 cells. The equation for
IC50 determination is Y¼ Bottomþ (Top Bottom)/(1þ 10^((LogIC50-
X)HillSlope)).
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tumor cells [41]. Moreover, hyaluronan-CD44 bind-
ing influences the activity of several downstream
signalling pathways, namely the anti-apoptotic
MAPK (mitogen-activated protein kinase) and PI3K-
Akt pathways, consequently promoting tumor cell
proliferation, survival, motility, invasiveness, and
chemoresistance [42]. A few studies have shown
that hyaluronan-CD44 signalling promotes cisplatin
resistance in head and neck, and in lung cancers
[43,44]. Other chemoresistance-mediating hyaluronan-
dependent mechanisms have been described, namely
EGFR (epidermal growth factor receptor)-mediated
oncogenic signaling [45], or acquisition of cancer
stem cell properties due to CD44 interaction with
cancer stem cell markers and subsequent activation
of microRNAs [46]. Additional studies are necessary
to further clarify how cell surface interactions
among hyaluronan, CD44, CD147, and MCTs con-
tribute to initiate molecular responses that impair
chemotherapy—namely cisplatin—effects.
In our immunohistochemistry study, we also
evaluatedCAIX expression, a catalyst that contributes
to the generation of the acid-resistant phenotype
under hypoxic conditions [47]. We observed that the
vast majority of the UBC samples expressed this
biomarker, with the luminal face of NMI papillary
tumors and the tumor core in MI lesions being
intensely stained. CAIX positivity was predominant
in high-grade papillary tumors, and seemed to
associate with a low aggressiveness profile. Several
authors have also reported a higher expression of
CAIX in NMI than in MI tumors [15,48], although
their reports generally pointed out for an association
between CAIX upregulation and occurrence of recur-
rence, progression and poor overall survival. In the
study by Hussain et al. [48], there was a tendency
towards longer survival for patients with tumors
expressing CAIX strongly. Probably, in their study,
as well as in our cohort, the high rate of CAIX
expression in papillary lesions influenced the clinico-
pathological and survival data. Interestingly, signifi-
cant associations were found when we compared
immunoreactive samples for MCT4, CD147, and
CD44 with CAIX plasma membrane positive cases.
These results most likely reflect the adjustment
to a hypoxia-mediated glycolytic metabolism that
upregulates MCTs and their chaperones.
Our important results on the prognostic and
platinum-response discriminatory significance of
CD147 in UBC patients led us to further explore its
biological role in an in vitro assay. We started by
confirming the expression of CD147, MCT1, and
MCT4 in four parental UBC cell lines. We then
characterized the effect of cisplatin treatment on cell
viability, cell cycle distribution and cell death.
Different responses were obtained, which probably
reflects the natural heterogeneity in UBC pathology,
biology and response to treatment. Overall, the NMI
5637 cell line and the MI T24 cell line were the most
sensitive to cisplatin treatment, as observed by the
effective decrease in cell viability, the increase in S and
subG1 phase cell populations, and the higher apopto-
tic rate. Similar results were obtained by Pinto-Leite
et al. [49]. The MI HT1376 and MCR cell lines were
less sensitive to cisplatin treatment, with the drug
exerting a cytostatic effect on these cells, as confirmed
by thehigher IC50 value, and the cell cycle/deathdata.
Based on these observations, we downregulated
CD147 expression on MCR and HT1376 cells using
the RNA interference (siRNA) approach, although we
were not able to conclude the assay with MCR cells,
since they did not tolerate CD147 downregulation
plus cisplatin treatment. The suppression of CD147
expression in a single UBC cell line could be a
limitation, together with the possible generation of
false positives due to off-target effects inherent to the
use of a single siRNA construct. Despite this, CD147
silencing in HT1376 cells was accompanied by a
marked decrease in MCT1 and MCT4 expressions,
confirming that MCTs rely on CD147 for their proper
expression and function. Moreover, CD147 down-
regulation clearly increased chemosensitivity to
cisplatin, which supports the hypothesis that this
multifunctional protein mediates chemoresistance in
UBC. In accordance, Wang et al. [50] and Zhu et al.
[51] used a similar approach in gastric and laryngeal
cell lines, and also demonstrated that suppression of
CD147 expression sensitizes cells to cisplatin.
In summary, our findings indicate that microenvi-
ronment-related molecules, particularly CD147 and
MCT1, are implicated in bladder cancer progression
and resistance to cisplatin-based chemotherapy,
unraveling new possibilities for target therapeutic
intervention. Improvement of the methodological
approach for obtaining cisplatin resistant UBC sub-
lines (with an intermittent stepwise selection proto-
col), and additional in vitro and in vivo studies, are
warranted to clarify the molecular mechanisms
involved in this biological scenario.
ACKNOWLEDGMENTS
We thank Prof. Paula Videira for providing the
bladder cancer cell lines, to Dr. Rosa´rio Pinto-Leite for
cell line authentication, and to the Pharmaceutical
Services of the Portuguese Institute of Oncology for
providing the stock solutions of cisplatin. This study
was supported by the Life and Health Sciences
Research Institute (ICVS) from the School of Health
Sciences of the University of Minho. VM-G received
a PhD fellowship from the Portuguese Science and
Technology Foundation (FCT, ref. SFRH/BD/51997/
2012).
REFERENCES
1. Colombel M, Soloway M, Akaza H, et al. Epidemiology,
staging, grading, and risk stratiﬁcation of bladder cancer. Eur
Urol Suppl 2008;7:618–626.
14 AFONSO ET AL.
Molecular Carcinogenesis
2. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent
advances in the diagnosis and treatment of bladder cancer.
BMC Med 2013;11:13.
3. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of
cisplatin resistance. Oncogene 2012;31:1869–1883.
4. Weidle UH, ScheuerW, Eggle D, Klostermann S, Stockinger H.
Cancer-related issues of CD147. Cancer Genomics Proteomics
2010;7:157–169.
5. Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin:
Partners in cancer cell chemoresistance. Drug Resist Updat
2008;11:110–121.
6. Slomiany MG, Grass GD, Robertson AD, et al. Hyaluronan,
CD44, and emmprin regulate lactate efﬂux and membrane
localization of monocarboxylate transporters in human breast
carcinoma cells. Cancer Res 2009;69:1293–1301.
7. Halestrap AP. The SLC16 gene family–Structure, role and
regulation in health and disease. Mol Aspects Med 2013;
34:337–349.
8. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P.
TheWarburg effect: Insights from the past decade. Pharmacol
Ther 2013;137:318–330.
9. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent
phenotypes: Why do cancers have high glycolysis? J Bioenerg
Biomembr 2007;39:251–257.
10. Brahimi-Horn MC, Bellot G, Pouyssegur J. Hypoxia and
energetic tumour metabolism. Curr Opin Genet Dev 2011;
21:67–72.
11. Xue YJ, Lu Q, Sun ZX. CD147 overexpression is a prognostic
factor and a potential therapeutic target in bladder cancer.
Med Oncol 2011;28:1363–1372.
12. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and
survivin predict response and survival following cisplatin-
containing chemotherapy in patients with advanced bladder
cancer. Clin Cancer Res 2007;13:4407–4414.
13. Afonso J, Longatto-Filho A, Baltazar F, et al. CD147 over-
expression allows an accurate discrimination of bladder cancer
patients' prognosis. Eur J Surg Oncol 2011;37:811–817.
14. Omran OM, Ata HS. CD44s and CD44v6 in diagnosis and
prognosis of human bladder cancer. Ultrastruct Pathol 2012;
36:145–152.
15. Klatte T, Seligson DB, Rao JY, et al. Carbonic anhydrase IX in
bladder cancer: A diagnostic, prognostic, and therapeutic
molecular marker. Cancer 2009;115:1448–1458.
16. Takata R, Katagiri T, Kanehira M, et al. Predicting response to
methotrexate, vinblastine, doxorubicin, and cisplatin neo-
adjuvant chemotherapy for bladder cancers through genome-
wide gene expression proﬁling. Clin Cancer Res 2005;11:
2625–2636.
17. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M,
Schmitt FC, Baltazar F. Role of monocarboxylate transporters
in human cancers: State of the art. J Bioenerg Biomembr
2012;44:127–139.
18. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK.
Role of CD44 in tumour progression and strategies for
targeting. J Drug Target 2012;20:561–573.
19. Supuran CT. Inhibition of carbonic anhydrase IX as a novel
anticancer mechanism. World J Clin Oncol 2012;3:98–103.
20. Amin MB, Srigley JR, Grignon DJ, et al. Urinary bladder cancer
protocols and checklists. Northﬁeld: College of American
Pathologists 2005.
21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A.
AJCC Cancer Staging Manual. New York: Springer Verlag;
2010.
22. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and
Genetics of Tumours of the Urinary System and Male Genital
Organs. Lyon: IARC Press 2004.
23. Pinto-Leite R, Carreira I, Melo J, et al. Genomic characterization
of three urinary bladder cancer cell lines: Understanding
genomic types of urinary bladder cancer. Tumour Biol 2014.
24. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F,
Baltazar F. Expression of monocarboxylate transporters 1, 2
and 4 in human tumours and their associationwith CD147 and
CD44. J Biomed Biotechnol 2010;2010:427694.
25. Pinheiro C, Sousa B, Albergaria A, et al. GLUT1 and CAIX
expression proﬁles in breast cancer correlate with adverse
prognostic factors and MCT1 overexpression. Histol Histo-
pathol 2011;26:1279–1286.
26. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, et al.
Monocarboxylate transporter 4 (MCT4) and CD147 over-
expression is associated with poor prognosis in prostate
cancer. BMC Cancer 2011;11:312.
27. Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU
International Consultation on Bladder Cancer 2012: Chemo-
therapy for urothelial carcinoma-neoadjuvant and adjuvant
settings. Eur Urol 2013;63:58–66.
28. Harper BW, Krause-Heuer AM, Grant MP, Manohar M,
Garbutcheon-Singh KB, Aldrich-Wright JR. Advances in
platinum chemotherapeutics. Chemistry 2010;16:7064–7077.
29. Schiavoni G, Gabriele L, Mattei F. The tumor microenviron-
ment: A pitch for multiple players. Front Oncol 2013;3:90.
30. Benton CR, Campbell SE, Tonouchi M, Hatta H, Bonen A.
Monocarboxylate transporters in subsarcolemmal and inter-
myoﬁbrillar mitochondria. Biochem Biophys Res Commun
2004;323:249–253.
31. Miranda-Goncalves V, Honavar M, Pinheiro C, et al. Mono-
carboxylate transporters (MCTs) in gliomas: Expression and
exploitation as therapeutic targets. Neuro Oncol 2013;15:
172–188.
32. Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ,
Halestrap AP. Basigin (CD147) is the target for organomercu-
rial inhibition of monocarboxylate transporter isoforms 1 and
4: The ancillary protein for the insensitive MCT2 is EMBIGIN
(gp70). J Biol Chem 2005;280:27213–27221.
33. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN,
Halestrap AP. CD147 is tightly associated with lactate
transporters MCT1 and MCT4 and facilitates their cell surface
expression. EMBO J 2000;19:3896–3904.
34. Pinheiro C, Longatto-Filho A, Simoes K, et al. The prognostic
value of CD147/EMMPRIN is associatedwithmonocarboxylate
transporter 1 co-expression in gastric cancer. Eur J Cancer
2009;45:2418–2424.
35. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarbox-
ylate transporter 4 regulates maturation and trafﬁcking of
CD147 to the plasma membrane in the metastatic breast
cancer cell line MDA-MB-231. Cancer Res 2007;67:4182–
4189.
36. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of
multidrug resistance in cancer cells by hyaluronan. J Biol Chem
2003;278:25285–25288.
37. Marieb EA, Zoltan-Jones A, Li R, et al. Emmprin promotes
anchorage-independent growth in human mammary carcino-
ma cells by stimulating hyaluronan production. Cancer Res
2004;64:1229–1232.
38. Toole BP. Hyaluronan: From extracellular glue to pericellular
cue. Nat Rev Cancer 2004;4:528–539.
39. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion
molecules to signalling regulators. Nat Rev Mol Cell Biol
2003;4:33–45.
40. KramerMW, Escudero DO, Lokeshwar SD, et al. Association of
hyaluronic acid family members (HAS1, HAS2, and HYAL-1)
with bladder cancer diagnosis and prognosis. Cancer 2011;
117:1197–1209.
41. Rudrabhatla SR, Mahaffey CL, Mummert ME. Tumor micro-
environment modulates hyaluronan expression: The lactate
effect. J Invest Dermatol 2006;126:1378–1387.
42. Toole BP. Hyaluronan-CD44 Interactions in Cancer: Paradoxes
and Possibilities. Clin Cancer Res 2009;15:7462–7468.
43. Ohashi R, Takahashi F, Cui R, et al. Interaction between CD44
and hyaluronate induces chemoresistance in non-small cell
lung cancer cell. Cancer Lett 2007;252:225–234.
44. Torre C, Wang SJ, Xia W, Bourguignon LY. Reduction of
hyaluronan-CD44-mediated growth, migration, and cisplatin
CD147 AND MCT1 IN BLADDER CANCER 15
Molecular Carcinogenesis
resistance in head and neck cancer due to inhibition of Rho
kinase and PI-3 kinase signaling. Arch Otolaryngol Head Neck
Surg 2010;136:493–501.
45. Wang SJ, Bourguignon LY. Hyaluronan and the interaction
between CD44 and epidermal growth factor receptor in
oncogenic signaling and chemotherapy resistance in head and
neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:
771–778.
46. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-
CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-
302 expression leading to self-renewal, clonal formation, and
cisplatin resistance in cancer stem cells from head and neck
squamous cell carcinoma. J Biol Chem 2012;287:32800–
32824.
47. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of
tumor pH and the role of carbonic anhydrase 9. Cancer
Metastasis Rev 2007;26:299–310.
48. Hussain SA, Palmer DH, Ganesan R, et al. Carbonic anhydrase
IX, a marker of hypoxia: Correlation with clinical outcome in
transitional cell carcinoma of the bladder. Oncol Rep 2004;
11:1005–1010.
49. Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, et al.
Everolimus combined with cisplatin has a potential role in
treatment of urothelial bladder cancer. Biomed Pharmacother
2013;67:116–121.
50. Wang B, Xu YF, He BS, et al. RNAi-mediated silencing of
CD147 inhibits tumor cell proliferation, invasion and increases
chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp
Clin Cancer Res 2010;29:61.
51. Zhu C, Pan Y, He B, et al. Inhibition of CD147 gene
expression via RNA interference reduces tumor cell invasion,
tumorigenicity and increases chemosensitivity to cisplatin
in laryngeal carcinoma Hep2 cells. Oncol Rep 2011;25:425–
432.
16 AFONSO ET AL.
Molecular Carcinogenesis
